G1 Therapeutics (NASDAQ: GTHX) had increased its price target with stock analysts at JPMorgan Chase & Co. from $ 58.00 to $ 63.00 in a study letter issued to investors on Friday 10 August. The brokerage currently has an "overweight" rating on the shares. The price target of JPMorgan Chase & Co. points to a potential advantage of 8.51% compared to the previous closure of the company.
GTHX has been the subject of several other research reports. ValuEngine has upgraded G1 Therapeutics from a "sell" classification to a "hold" rating in a study letter on Wednesday 2 May. HC Wainwright started the coverage on G1 Therapeutics in a study letter on Tuesday 29 May. They set a "buy" rating and a $ 61.00 price target for the company. Needham & Company LLC increased its price target on G1 Therapeutics from $ 42.00 to $ 60.00 and gave the shares a "buy" score in a research report on Friday, May 18. BidaskClub cut G1 Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 31. Finally, Zacks Investment Research G1 Therapeutics brought a "sell" classification to a "hold" classification in a research report on Tuesday, May 15. One investment analyst assessed the shares with a hold rating, six gave a buy rating and one gave a strong buy-rating to the company. G1 Therapeutics has a consensus score of & # 39; Buy & # 39; and a consensus price target of $ 58.00.
GTHX opened at $ 58.06 on Friday. The stock has a market capitalization of $ 1.92 billion, a PE ratio of -16.26 and a beta of -1.59. G1 Therapeutics has a low of 52 weeks of $ 16.26 and a height of 52 weeks of $ 64.83.
G1 Therapeutics (NASDAQ: GTHX) last published its quarterly results on Wednesday 8 August. The company reported ($ 0.64) earnings per share (EPS) for the quarter, in addition to the consensus estimate of ($ 0.65) with $ 0.01. Research analysts expect that G1 Therapeutics will report -2.7 earnings per share for the current year.
In related news, SVP Terry L. Murdock sold 3,519 shares in the company's shares in a transaction on Friday 3 August. The stock was sold at an average price of $ 50.60 for a total transaction of $ 178,061.40. The transaction was disclosed in a legal application to the Securities & Exchange Commission, which is accessible via this link. VP Jennifer K. Moses also sold 750 shares of the company's shares in a transaction on Tuesday 5 June. The stock has been sold at an average price of $ 38.77, for a total value of $ 29,077.50. The information for this sale can be found here. In the past three months, Insiders have sold a total of 829,545 shares of the company's shares to the value of $ 39,843,391. 15.92% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of the company. FMR LLC grew 1.2% in G1 Therapeutics in the second quarter. FMR LLC now owns 4,902,732 shares of the company's shares worth $ 213,073,000 after acquiring 57,156 additional shares during the last quarter. BlackRock Inc. has lifted its stake in G1 Therapeutics by 32.0% in the second quarter. BlackRock Inc. now owns 1,690,360 shares of the company's shares with a value of $ 73,462,000 after the acquisition of an additional 409,300 shares during the period. Bank of New York Mellon Corp increased its stake in G1 Therapeutics by 1.497.7% in the second quarter. Bank of New York Mellon Corp now holds 1,262,991 shares of the company's shares worth $ 54,890,000 after the purchase of 1,183,940 additional shares during the period. Voya Investment Management LLC increased its stake in G1 Therapeutics by 7.889.9% in the second quarter. Voya Investment Management LLC now owns 449,834 shares of the company's shares with a value of $ 19,550,000 after the purchase of an additional 444,204 shares during the period. Finally, BB Biotech AG acquired a new position in G1 Therapeutics shares in the 2nd quarter, worth $ 15,324,000. 63.98% of the shares are owned by hedge funds and other institutional investors.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc., a biopharmaceutical company in clinical phase, focuses on the discovery, development and commercialization of novel small molecule therapeutics for the treatment of cancer patients in the United States. It develops trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is part of Phase 1b / 2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first- / second- / third- rule metastatic triple-negative breast cancer; G1T38, an oral CDK4 / 6 inhibitor that is phase 1b / 2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Recommended story: closed-end investment funds
Receive news and ratings for G1 Therapeutics Daily – Enter your email address below to receive a concise, daily summary of the latest news and reviews from analysts for G1 Therapeutics and related companies with the FREE daily email newsletter from MarketBeat.com.